Traditionally, Tregs have been associated with unfavorable clinical outcomes in invasive BC, potentially due to the immunosuppressive microenvironment fostered by transforming growth factor (TGF-β) and interleukin (IL)-2 stimuli [29,30]. The gene discussed is IL2; the disease is breast cancer.